Evaluating primary chemotherapy with temozolomide continuative low dose in patients with low grade gliomas grade II WHO.
Phase of Trial: Phase II
Latest Information Update: 22 Sep 2016
At a glance
- Drugs Temozolomide (Primary)
- Indications Glioma
- Focus Therapeutic Use
- Acronyms TCLGG
- 22 Sep 2016 Primary endpoint (Progression free survival at 12 and 24 months) has not been met,according to the results published in the Tumori.
- 22 Sep 2016 Results published in the Tumori
- 07 Jun 2011 New trial record